Diligence memo · auto-generated · as of July 2, 2026
Pure Green Pharmaceuticals Inc.
Pure Green Pharmaceuticals Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Pure Green Pharmaceuticals Inc. operates in Pharmaceuticals, based in WEST BLOOMFIELD.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pure Green Pharmaceuticals Inc. has raised $5.4M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.4M on 2022-11-10.
Most recent recorded round closed around 2022-11-10.
Valuation (modeled)modeled
Provath models Pure Green Pharmaceuticals Inc. at approximately $58M (range $6.2M–$185M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.79× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 3.6 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 43% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 46% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.